Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study
Journal Article
·
· Cancer (Philadelphia); (USA)
DOI:https://doi.org/10.1002/1097-0142(19900201)65:3<400::AID-CNCR2820650304>3.0.CO;2-H·
OSTI ID:7190677
- Centro di Riferimento Oncologico, Aviano (Italy)
Between June 1980 and December 1983, 111 patients with inoperable epidermoid bronchogenic carcinoma (limited disease) were entered into a randomized trial comparing radiotherapy alone versus radiotherapy and combination chemotherapy with cyclophosphamide, Adriamycin (doxorubicin), methotrexate, and procarbazine. Thirty-five of 62 (56.4%) patients treated with 4500 rad in 15 fractions in 3 weeks and 19 of 49 (38.8%) patients treated with the same radiation treatment and chemotherapy had an objective response. The difference in response rate was not significant (P = 0.900). Median time to progression was 5.9 and 7.02 months, respectively, for the radiation treatment and the combined treatment. Median survival was 11.74 and 10.03 months, respectively, without statistically significant differences between the two groups of patients. The toxicity was acceptable and no treatment-related death occurred in either treatment schedule. In this study no significant superiority of combined radiotherapy and chemotherapy treatment over radiation therapy alone was evidenced. Whether different chemotherapy regimens may prove more effective in this context should be clarified by further studies.
- OSTI ID:
- 7190677
- Journal Information:
- Cancer (Philadelphia); (USA), Journal Name: Cancer (Philadelphia); (USA) Vol. 65:3; ISSN 0008-543X; ISSN CANCA
- Country of Publication:
- United States
- Language:
- English
Similar Records
Combined radiotherapy and chemotherapy with cyclophosphamide, adriamycin, methotrexate, procarbazine (camp) in 64 consecutive patients with epidermoid bronchogenic carcinoma, limited disease: a prospective study. [/sup 60/Co]
Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity
Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP): effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma
Journal Article
·
Tue Jun 01 00:00:00 EDT 1982
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6783081
Sequential radiotherapy and adriamycin in the management of bronchogenic carcinoma: the question of additive toxicity
Conference
·
Wed Aug 01 00:00:00 EDT 1979
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:5339501
Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP): effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma
Journal Article
·
Wed Sep 01 00:00:00 EDT 1976
· Cancer Treat. Rep.; (United States)
·
OSTI ID:6010191